Abraxis Pharmaceutical Products fulfills an important need in the medical community as a provider of a broad portfolio of multi-source and branded injectable pharmaceutical products, including difficult to manufacture, urgently needed medical products.
APP has a portfolio of more than 150 products and is among the market leaders in each of its areas of focus—oncology, anti-infective and critical care injectable pharmaceuticals. The company has a deep pipeline of approximately 50 products in various stages of development, which includes a number of product applications pending at the FDA. APP has expanded its product portfolio and is among the industry leaders in ANDA approvals with 45 product approvals between 2001 and 2005. As of September 2006, the company continued this momentum with nine (including two tentative approvals) new generic product approvals from the FDA.